GlassScriptPhysician profile
Laura B Moore
NPI 1619926177
$2,632.19
in general payments reported to CMS, 2019-2025
18 companies · $673 in 2025
The $673 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $39.76 · 2022: $566 · 2023: $748 · 2024: $607 · 2025: $673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,027.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,026.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $549.11 | 2022-2025 | |
| Novo Nordisk INC | $479.45 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $461.19 | 2022-2025 | |
| Lilly USA, LLC | $438.28 | 2021-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $173.57 | 2024-2025 | Airsupra, Breztri |
| Pfizer INC. | $128.94 | 2024-2025 | |
| Exact Sciences Corporation | $103.06 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $53.09 | 2022 | |
| Genentech USA, INC. | $42.18 | 2024 | Xolair |
| Astellas Pharma US INC | $41.15 | 2024-2025 | Veozah |
| Amgen INC. | $29.13 | 2022-2023 | Repatha |
| Novartis Pharmaceuticals Corporation | $27.93 | 2024 | |
| Kyowa Kirin, INC. | $23.40 | 2025 | |
| Corcept Therapeutics | $19.61 | 2025 | Korlym |
| Acadia Pharmaceuticals INC | $18.62 | 2025 | Daybue |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $15.58 | 2024 | Auvelity |
| Exeltis, USA INC. | $14.57 | 2025 | Slynd |
| Glaxosmithkline, LLC. | $13.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.